The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 18, Parabilis Medicines announced a collaboration with Regeneron to develop therapies using the Helicon peptide platform. The agreement includes a $50 million upfront payment and a $75 million equity commitment from Regeneron. Potential milestone payments could reach up to $2.2 billion plus tiered royalties.